Millipore Sigma Vibrant Logo

05-23-0101 Angiotensin II, Human - CAS 4474-91-3 - Calbiochem

Plays an important role in the regulation of blood pressure.

Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: DRVYIHPF

Primary Target: adenylate cyclase activity
View Products on Sigmaaldrich.com
05-23-0101
Ver precios y disponibilidad

Descripción

Replacement Information

Tabla espec. clave

CAS #Empirical Formula
4474-91-3C₅₀H₇₁N₁₃O₁₂

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
05-23-0101-25MG
Comprobando disponibilidad...
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      		 Frasco de vidrio 25 mg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      —
      Solicitar precio
      		 —
      Description
      OverviewPlays an important role in the regulation of blood pressure. Stimulates the release of aldosterone from the adrenal gland. Inhibits adenylate cyclase activity in spontaneously hypertensive rats. Has strong vasoconstrictive effects. Increases the entry of Ca2+ in heart muscle via voltage-sensitive channels and activates myosin light chain kinase. Also elicits an increase in voltage-dependent delayed rectifier K+ current in neurons. Activates JAK2 in smooth muscle cells. Activates p125FAK and a cytosolic 115-120 kDa calcium-dependent tyrosine kinase in rat epithelial cells. Also activates p60c-src as well as ERK1/2, JNK, and p38 MAP Kinase in vascular smooth muscle cells.
      Catalogue Number05-23-0101
      Brand Family Calbiochem®
      SynonymsDRVYIHPF
      References
      ReferencesZhu, M., et al. 2000. J. Neurophysiol. 84, 2494.
      Natarajan, R., et al. 1999. Hypertension 33, 378.
      Mazzolai, L., et al. 1998. Hypertension 31, 1324.
      Earp, H.S., et al. 1995. J. Biol. Chem. 270, 28440.
      Ishida, M., et al. 1995. Circ. Res. 77, 1053.
      Vyas, S.J., and Jackson, E.K. 1995. J. Pharmacol. Exp. Ther. 273, 768.
      Product Information
      CAS number4474-91-3
      ATP CompetitiveN
      FormWhite to off-white solid
      Hill FormulaC₅₀H₇₁N₁₃O₁₂
      Chemical formulaC₅₀H₇₁N₁₃O₁₂
      Hygroscopic Hygroscopic
      ReversibleN
      Sold on the basis of peptide contentY
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetadenylate cyclase activity
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableN
      Peptide ContentY
      Peptide SequenceH-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSBW2165000
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 week at 4°C or for up to 1 month at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      05-23-0101-25MG 04055977206913

      Documentation

      Angiotensin II, Human - CAS 4474-91-3 - Calbiochem Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Angiotensin II, Human - CAS 4474-91-3 - Calbiochem Certificados de análisis

      CargoNúmero de lote
      05-23-0101

      Referencias bibliográficas

      Visión general referencias
      Zhu, M., et al. 2000. J. Neurophysiol. 84, 2494.
      Natarajan, R., et al. 1999. Hypertension 33, 378.
      Mazzolai, L., et al. 1998. Hypertension 31, 1324.
      Earp, H.S., et al. 1995. J. Biol. Chem. 270, 28440.
      Ishida, M., et al. 1995. Circ. Res. 77, 1053.
      Vyas, S.J., and Jackson, E.K. 1995. J. Pharmacol. Exp. Ther. 273, 768.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision12-May-2008 JSW
      SynonymsDRVYIHPF
      DescriptionFunctions in blood pressure maintenance. Stimulates the release of aldosterone from the adrenal gland. Has strong vasoconstrictive effects. Increases the entry of Ca2+ in heart muscle via voltage-sensitive channels and activates myosin light chain kinase. Activates JAK2 in smooth muscle cells. Activates p125FAK and a cytosolic 115-120 kDa calcium-dependent tyrosine kinase in rat epithelial cells. Also activates pp60c-src in vascular smooth muscle cells. Inhibits adenylate cyclase activity in spontaneously hypertensive rats.
      FormWhite to off-white solid
      CAS number4474-91-3
      RTECSBW2165000
      Chemical formulaC₅₀H₇₁N₁₃O₁₂
      Peptide SequenceH-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH
      Purity≥98% by HPLC
      Solubility5% acetic acid (1 mg/ml) or H₂O (1 mg/ml)
      Storage -20°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 week at 4°C or for up to 1 month at -20°C.
      Toxicity Standard Handling
      Merck USA index14 651
      ReferencesZhu, M., et al. 2000. J. Neurophysiol. 84, 2494.
      Natarajan, R., et al. 1999. Hypertension 33, 378.
      Mazzolai, L., et al. 1998. Hypertension 31, 1324.
      Earp, H.S., et al. 1995. J. Biol. Chem. 270, 28440.
      Ishida, M., et al. 1995. Circ. Res. 77, 1053.
      Vyas, S.J., and Jackson, E.K. 1995. J. Pharmacol. Exp. Ther. 273, 768.